T. Rowe Price Associates’s Aratana Therapeutics, Inc. PETX Stock Holding History

T. Rowe Price Associates’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-26,200	Closed	-$161K	–	2644
2017 Q3	$161K	Buy	26,200 +12,700	+94%	+$80.4K	﹤0.01%	2448
2017 Q2	$98K	Buy	13,500 +3,100	+30%	+$19.1K	﹤0.01%	2483
2017 Q1	$55K	Hold	10,400	–	–	﹤0.01%	2538
2016 Q4	$75K	Hold	10,400	–	–	﹤0.01%	2496
2016 Q3	$97K	Sell	10,400 -92,201	-90%	-$766K	﹤0.01%	2448
2016 Q2	$648K	Hold	102,601	–	–	﹤0.01%	1855
2016 Q1	$566K	Hold	102,601	–	–	﹤0.01%	1918
2015 Q4	$573K	Buy	102,601 +100	+0.1%	+$661	﹤0.01%	1900
2015 Q3	$867K	Buy	+102,501	New	+$1.73M	﹤0.01%	1749

Other funds holding PETX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

AIC

AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

T. Rowe Price Associates's PETX Position: Q4 2017 in Review

T. Rowe Price Associates sold out of Aratana Therapeutics, Inc. (PETX) in Q4 2017, closing a stake of 26,200 shares — an estimated $161K sold.

T. Rowe Price Associates first reported a position in PETX in Q3 2015 and held it in 9 quarters. The position peaked at $867K in Q3 2015. 105 funds tracked by Wall St. Rank hold PETX as of Q4 2017.

T. Rowe Price Associates reported no remaining Aratana Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
T. Rowe Price Associates sold 26,200 Aratana Therapeutics, Inc. shares in Q4 2017, an estimated $161K.
T. Rowe Price Associates first reported a position in Aratana Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
T. Rowe Price Associates's Aratana Therapeutics, Inc. position peaked at $867K in Q3 2015.
105 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q4 2017.

Based on T. Rowe Price Associates's 13F filing for Q4 2017, filed 14 Feb 2018.